Discovery of new dual binding TNKS inhibitors of Wnt signaling inhibition by pharmacophore modeling, molecular docking and bioassay.

Tankyrases (TNKS), key transmitters in the Wnt signaling pathway which is very conservative in evolution, are vital targets as they are overexpressed widely in many cancers. In this work, 5 inhibitors with novel structures have been discovered and validated using the ligand-based (pharmacophore) virtual screening, docking study, and Luciferase reporter assays for Wnt signaling. Among them, PYL-1, in particular, was the most potent inhibitor with an IC50 value of 9.56 μM against Wnt signaling. The analysis of binding modes was performed to further understand the vital interactions between inhibitors and TNKS 2, and the five hits belong to dual site inhibitors. This work could be helpful for the design and development of novel dual binders as TNKS inhibitors.

[1]  Hans Clevers,et al.  Mining the Wnt pathway for cancer therapeutics , 2006, Nature Reviews Drug Discovery.

[2]  Diogo Santos-Martins,et al.  Receptor-based virtual screening protocol for drug discovery. , 2015, Archives of biochemistry and biophysics.

[3]  S. Aaronson,et al.  Scaffold hopping approach on the route to selective tankyrase inhibitors. , 2014, European journal of medicinal chemistry.

[4]  T. Tsuruo,et al.  Tankyrase 1 as a target for telomere-directed molecular cancer therapeutics. , 2005, Cancer cell.

[5]  Lawrence Lum,et al.  Small molecule-mediated disruption of Wnt-dependent signaling in tissue regeneration and cancer , 2008, Nature chemical biology.

[6]  H. Bregman,et al.  Discovery of a class of novel tankyrase inhibitors that bind to both the nicotinamide pocket and the induced pocket. , 2013, Journal of medicinal chemistry.

[7]  Asad U Khan,et al.  Structure based virtual screening to discover putative drug candidates: necessary considerations and successful case studies. , 2015, Methods.

[8]  T. Mitchison,et al.  Tankyrase-1 polymerization of poly(ADP-ribose) is required for spindle structure and function , 2005, Nature Cell Biology.

[9]  T. Mitchison,et al.  Interaction between Poly(ADP-ribose) and NuMA contributes to mitotic spindle pole assembly. , 2009, Molecular biology of the cell.

[10]  T. Lange,et al.  Tankyrase promotes telomere elongation in human cells , 2000, Current Biology.

[11]  H. Bregman,et al.  Development of novel dual binders as potent, selective, and orally bioavailable tankyrase inhibitors. , 2013, Journal of medicinal chemistry.

[12]  L. Lehtiö,et al.  Structural basis of selective inhibition of human tankyrases. , 2012, Journal of medicinal chemistry.

[13]  L. Lehtiö,et al.  Evaluation and Structural Basis for the Inhibition of Tankyrases by PARP Inhibitors. , 2014, ACS medicinal chemistry letters.

[14]  Xin Huang,et al.  Novel Binding Mode of a Potent and Selective Tankyrase Inhibitor , 2012, PloS one.

[15]  L. Tessarollo,et al.  Tankyrase 1 and Tankyrase 2 Are Essential but Redundant for Mouse Embryonic Development , 2008, PloS one.

[16]  F. Lombardo,et al.  Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings , 1997 .

[17]  L. Lehtiö,et al.  Structural Basis and Selectivity of Tankyrase Inhibition by a Wnt Signaling Inhibitor WIKI4 , 2013, PloS one.

[18]  Susan Smith,et al.  NuMA is a major acceptor of poly(ADP-ribosyl)ation by tankyrase 1 in mitosis. , 2005, The Biochemical journal.

[19]  Guo-Lei Zhu,et al.  Cycloartane Glycosides from the Roots of Cimicifuga foetida with Wnt Signaling Pathway Inhibitory Activity , 2015, Natural Products and Bioprospecting.

[20]  A. Ashworth,et al.  Tankyrase-targeted therapeutics: expanding opportunities in the PARP family , 2012, Nature Reviews Drug Discovery.

[21]  R. W. Hansen,et al.  The price of innovation: new estimates of drug development costs. , 2003, Journal of health economics.

[22]  C. Harley,et al.  Stabilization of short telomeres and telomerase activity accompany immortalization of Epstein-Barr virus-transformed human B lymphocytes , 1994, Journal of virology.

[23]  D. Quinn,et al.  Acetylcholinesterase: enzyme structure, reaction dynamics, and virtual transition states , 1987 .

[24]  P. Polakis.  The many ways of Wnt in cancer. , 2007, Current opinion in genetics & development.

[25]  W. Marsden.  I and J , 2012 .

[26]  R. Stephenson.  A and V , 1962, The British journal of ophthalmology.

[27]  Bernhard Lüscher,et al.  Toward a unified nomenclature for mammalian ADP-ribosyltransferases. , 2010, Trends in biochemical sciences.

[28]  S. Hsiao,et al.  Tankyrase function at telomeres, spindle poles, and beyond. , 2008, Biochimie.

[29]  K. Muthusamy,et al.  Sighting of tankyrase inhibitors by structure- and ligand-based screening and in vitro approach. , 2014, Molecular bioSystems.

[30]  J. Weigelt,et al.  Family-wide chemical profiling and structural analysis of PARP and tankyrase inhibitors , 2012, Nature Biotechnology.

[31]  Stephen R. Johnson,et al.  Molecular properties that influence the oral bioavailability of drug candidates. , 2002, Journal of medicinal chemistry.

[32]  H. Dinh,et al.  A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice. , 2012, Cancer research.

[33]  J. Steitz,et al.  Telomere shortening associated with chromosome instability is arrested in immortal cells which express telomerase activity. , 1992, The EMBO journal.

[34]  O. Werz,et al.  Regulation of tumorigenic Wnt signaling by cyclooxygenase-2, 5-lipoxygenase and their pharmacological inhibitors: A basis for novel drugs targeting cancer cells? , 2016, Pharmacology & therapeutics.

[35]  Richard D. Taylor,et al.  Improved protein–ligand docking using GOLD , 2003, Proteins.

[36]  Shan Feng,et al.  Discovery of N6-phenyl-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamine derivatives as novel CK1 inhibitors using common-feature pharmacophore model based virtual screening and hit-to-lead optimization. , 2012, European journal of medicinal chemistry.

[37]  V. Schreiber,et al.  The expanding field of poly(ADP-ribosyl)ation reactions. ‘Protein Modifications: Beyond the Usual Suspects' Review Series , 2008, EMBO reports.

[38]  A. Ashworth,et al.  Design and discovery of 3-aryl-5-substituted-isoquinolin-1-ones as potent tankyrase inhibitors , 2015 .

[39]  N. Zaffaroni,et al.  Targeting the telosome: therapeutic implications. , 2009, Biochimica et biophysica acta.

[40]  Marc W. Kirschner,et al.  Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling , 2009, Nature.

[41]  G. G. Stokes.  "J." , 1890, The New Yale Book of Quotations.

[42]  Ling-mei Kong,et al.  Biflavone Ginkgetin, a Novel Wnt Inhibitor, Suppresses the Growth of Medulloblastoma , 2015, Natural Products and Bioprospecting.